Patients not capable or willing to provide informed consent
Patients starting Adalimumab less than five half-lives after the interruption of a previous anti-TNF therapy.

NCT02035800_exc_T2
Drug
Adalimumab
NCT02035800_exc_T3
Temporal
less than five half-lives after the interruption of a previous anti-TNF therapy
NCT02035800_exc_T4
Reference_point
the interruption of a previous anti-TNF therapy
NCT02035800_exc_T5
Procedure
anti-TNF therapy
NCT02035800_exc_T6
Temporal
previous